Lexington, Ky.- December 7, 2016 - Dr. Ashlee E. Watts was a presenter at the annual American Association of Equine Practitioners (AAEP) conference in Orlando, Fla., detailing two years of clinical research results on the effects of Resveratrol on horses experiencing hock lameness. The study titled, "A randomized, controlled trial of the effects of Resveratrol administration in performance horses with lameness localized to the distal tarsal joints," provided proof that Equithrive® Joint is effective therapy for equine hock lameness.
Watts' research has created buzz in the horse world among veterinarians and caregivers as research in the equine supplement market is not commonly performed due to the time and cost involved. A board certified large animal surgeon in the Department of Large Animal Clinical Sciences at Texas A&M University, Watts is also Director of the Comparative Orthopedics and Regenerative Medicine Laboratory at Texas A&M University. The study was published in the Journal of the American Veterinary Medical Association.
Dr. Watts has been a presenter at AAEP numerous times since 2007. "The AAEP Annual Convention is a great opportunity to present clinically relevant research findings to equine veterinarians. This allows practitioners to stay up-to-date on the latest innovations and discoveries that are relevant to their patients and clients."
Pioneering Equine Supplement Research
Biological Prospects LLC, an animal health product developer and manufacturer located in Lexington, KY, is pioneering the use of the anti-inflammatory antioxidant resveratrol in the animal health field and developed Equithrive® Joint for use in horses.
Dr. Patrick Lawless is the Founder, President and CEO of Biological Prospects. "The equine supplement market provides equestrians with thousands of choices to improve the wellness of horses and ponies. However, due to the lack of scientific data, it can be confusing to sort through all the options when looking for a product to alleviate the rigors of performance for competition horses, or to bring relief to an aging and arthritic equine to improve quality of life," said Dr. Lawless. "As a company, we think it is important to back up marketing claims with the relevant scientific data."
Equithrive® is the pioneer in equine resveratrol therapy. Resveratrol has become known to the public as the healthy ingredient in red wine. Equithrive® has developed a proprietary Resveratrol product (Resverasyn®) that has been proven in multiple university studies to reduce lameness, inflammation and oxidative stress in horses. Excessive inflammation plays a major role in arthritis and in Equine Metabolic Syndrome (EMS). The company developed Equithrive® Joint to support healthy joint function in horses during aging, training and competition. Metabarol™ contains a higher dose of Resverasyn® and has been demonstrated to reduce insulin levels in EMS horses that are prone to foundering.
Veterinarians across the United States now routinely recommend Equithrive® Joint and Metabarol™ to support joint health and metabolic function in equine athletes and in older horses. Equithrive® is the global leader in Resveratrol therapy for horses. For more information about Equithrive®, please visit equithrive.com or call 866-721-1412.